🎉 M&A multiples are live!
Check it out!

Kissei Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Kissei Pharmaceutical and similar public comparables like Vivoryon Therapeutics, Julphar, and Galapagos.

Kissei Pharmaceutical Overview

About Kissei Pharmaceutical

Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company’s operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.


Founded

1946

HQ

Japan
Employees

2.1K+

Website

kissei.co.jp

Financials

LTM Revenue $576M

LTM EBITDA $80.2M

EV

$747M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Kissei Pharmaceutical Financials

Kissei Pharmaceutical has a last 12-month revenue of $576M and a last 12-month EBITDA of $80.2M.

In the most recent fiscal year, Kissei Pharmaceutical achieved revenue of $502M and an EBITDA of $124M.

Kissei Pharmaceutical expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Kissei Pharmaceutical valuation multiples based on analyst estimates

Kissei Pharmaceutical P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $449M $502M XXX XXX XXX
Gross Profit $208M $215M XXX XXX XXX
Gross Margin 46% 43% XXX XXX XXX
EBITDA $118M $124M XXX XXX XXX
EBITDA Margin 26% 25% XXX XXX XXX
Net Profit $85.9M $70.0M XXX XXX XXX
Net Margin 19% 14% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Kissei Pharmaceutical Stock Performance

As of April 15, 2025, Kissei Pharmaceutical's stock price is JPY 3635 (or $24).

Kissei Pharmaceutical has current market cap of JPY 156B (or $1.0B), and EV of JPY 112B (or $747M).

See Kissei Pharmaceutical trading valuation data

Kissei Pharmaceutical Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$747M $1.0B XXX XXX XXX XXX $1.67

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Kissei Pharmaceutical Valuation Multiples

As of April 15, 2025, Kissei Pharmaceutical has market cap of $1.0B and EV of $747M.

Kissei Pharmaceutical's trades at 1.3x LTM EV/Revenue multiple, and 9.3x LTM EBITDA.

Analysts estimate Kissei Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Kissei Pharmaceutical and 10K+ public comps

Kissei Pharmaceutical Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $747M XXX XXX XXX
EV/Revenue 1.3x XXX XXX XXX
EV/EBITDA 8.2x XXX XXX XXX
P/E 14.0x XXX XXX XXX
P/E/Growth -0.9x XXX XXX XXX
EV/FCF 22.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Kissei Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Kissei Pharmaceutical Valuation Multiples

Kissei Pharmaceutical's NTM/LTM revenue growth is -1%

Kissei Pharmaceutical's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Kissei Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Kissei Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Kissei Pharmaceutical and other 10K+ public comps

Kissei Pharmaceutical Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 12% XXX XXX XXX XXX
EBITDA Margin 16% XXX XXX XXX XXX
EBITDA Growth 5% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 16% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 44% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Kissei Pharmaceutical Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Kissei Pharmaceutical M&A and Investment Activity

Kissei Pharmaceutical acquired  XXX companies to date.

Last acquisition by Kissei Pharmaceutical was  XXXXXXXX, XXXXX XXXXX XXXXXX . Kissei Pharmaceutical acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Kissei Pharmaceutical

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Kissei Pharmaceutical

When was Kissei Pharmaceutical founded? Kissei Pharmaceutical was founded in 1946.
Where is Kissei Pharmaceutical headquartered? Kissei Pharmaceutical is headquartered in Japan.
How many employees does Kissei Pharmaceutical have? As of today, Kissei Pharmaceutical has 2.1K+ employees.
Who is the CEO of Kissei Pharmaceutical? Kissei Pharmaceutical's CEO is Mr. Mutsuo Kanzawa.
Is Kissei Pharmaceutical publicy listed? Yes, Kissei Pharmaceutical is a public company listed on TKS.
What is the stock symbol of Kissei Pharmaceutical? Kissei Pharmaceutical trades under 4547 ticker.
When did Kissei Pharmaceutical go public? Kissei Pharmaceutical went public in 1988.
Who are competitors of Kissei Pharmaceutical? Similar companies to Kissei Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Kissei Pharmaceutical? Kissei Pharmaceutical's current market cap is $1.0B
What is the current revenue of Kissei Pharmaceutical? Kissei Pharmaceutical's last 12-month revenue is $576M.
What is the current EBITDA of Kissei Pharmaceutical? Kissei Pharmaceutical's last 12-month EBITDA is $80.2M.
What is the current EV/Revenue multiple of Kissei Pharmaceutical? Current revenue multiple of Kissei Pharmaceutical is 1.3x.
What is the current EV/EBITDA multiple of Kissei Pharmaceutical? Current EBITDA multiple of Kissei Pharmaceutical is 9.3x.
What is the current revenue growth of Kissei Pharmaceutical? Kissei Pharmaceutical revenue growth between 2023 and 2024 was 12%.
Is Kissei Pharmaceutical profitable? Yes, Kissei Pharmaceutical is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.